ArticleVaccines2022

The Population-Wide Risk-Benefit Profile of Extending the Primary COVID-19 Vaccine Course Compared with an mRNA Booster Dose Program.

Tinevimbo Shiri et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.